π« This review analyzes the current evidence supporting established predictive #biomarkers, including PD-L1 expression, in the treatment of #NSCLC while highlighting their major limitations.
@stemcellsciencenews.com
@stemcellsciencenews.comπ« This review analyzes the current evidence supporting established predictive #biomarkers, including PD-L1 expression, in the treatment of #NSCLC while highlighting their major limitations.
@eaonc.bsky.socialThe EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM
@estroradiotherapy.bsky.socialπ Coming up 13 October! Join this multidisciplinary webinar exploring how to combine #Radiotherapy & #Immunotherapy in #NSCLC β from biology and treatment timing to dose, volume and advanced RT techniques.
π
13 Oct | 16:30β18:00 CEST | Online
π Reg: https://bit.ly/4hKH8D8
@jco-asco.bsky.socialDoes prior systemic chemotherapy exposure influence subsequent response to ROS1 tyrosine kinase inhibitors (TKIs) in ROS1-rearranged non-small-cell lung cancer? Learn more in this #JCOPO systematic review.
Read the article. https://bit.ly/4zc5BHH
@sigtrans-sttt.bsky.socialMycobacterium abscessus directly links the #TumorMicrobiome to #NSCLC mutagenesis, as bacterial NDK phosphorylates IRF3 to amplify interferon signaling and sustain #APOBEC3A-driven genomic diversification.
#STTT #OpenAccess: doi.org/10.1038/s413...
@onc-rg.bsky.socialπππ 2026 ππππ ππ½πΌ πππ£ππ¨πππ₯π: πππ¨πͺππ‘ππ―ππ.
Which mechanisms are commanding the late-breaker spotlight this year?
#ESMO2026 #ESMO26 #Oncology #NSCLC #SCLC #ADCs #vaccines #ClinicalData #DrugTrials #CompetitiveStrategy
@alliance-org.bsky.socialNew lung cancer trial open π§ͺπ«
Alliance A082402 is studying if targeted post op radiation (IΒ² PORT) can reduce recurrence in high risk #NSCLC patients after surgery while limiting side effects. Learn more https://bit.ly/I-PORT-Trial. #LungCancer #ClinicalTrials #RadiationTherapy
@yalecancer.bsky.socialBeatrice Katsnelson shared analysis of 2,186 patients with #NSCLC, noting KEAP1 & SMARCA4 tumor mutations predicted development of bone mets. Findings suggest molecular profiling could identify high-risk pts and increase surveillance strategies. #ASTRO26
@astro-org.bsky.social @oncoalert.bsky.social
@eaonc.bsky.social#ClinicalTrial EA5221/ACHIEVE, led by Dr. Megan Baumgart, aims to help older patients with #LungCancer live longer while also maintaining a good quality of life. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM
@yalecancer.bsky.socialNew data presented by Maneeth Ellendula @yaleschoolofmed.bsky.social #ASTRO2026 identifies SMARCA4 mutations as a predictor of brain mets in early-stage non-small lung cancer #NSCLC.
@astro-org.bsky.social @oncoalert.bsky.social
@myesmo.bsky.socialπ In this #ESMOGuidelines webinar, we explore the ESMO Clinical Practice Guidelines for early stage and locally advanced #NSCLC, applying key recommendations to a real-world case in multidisciplinary #LungCancer care
@genesndiseases.bsky.socialCould #tumor metabolism drive T-cell exhaustion?
CD147 enhances tryptophan uptake and kynurenine production in #NSCLC, promoting CD8+ T-cell exhaustion, while CD147-targeted CAR-T plus anti-PD-1 shows therapeutic potential.
#OpenAccess in #GenesAndDiseases: doi.org/10.1016/j.ge...
@estroradiotherapy.bsky.socialπ« Join the upcoming Lung Webinar for expert insights into combining RT and immunotherapy, from timing and dose to advanced RT techniques.
π 13 Oct | 16:30β18:00 CEST | Online
π Register: https://bit.ly/4hKH8D8
@sigtrans-sttt.bsky.socialFindings from a randomized phase III #ClinicalTrial showed that mefatinib improved progression-free survival vs gefitinib, with a pronounced benefit in #EGFR L858R-mutated #NSCLC and comparable outcomes in exon 19 deletion.
@lungcancereurope.bsky.socialEarlier #lungcancer testing found no target. Broader genomic profiling found a driver alteration in 37%.
π Japanese study inclu 2,296 people with advanced or recurrent #NSCLC.
For Europe we need the right test, early enough, followed by trtmt that matches the result.
@sigtrans-sttt.bsky.socialHow can #NSCLC escape #EGFR inhibition?
RAF1 amplification on extrachromosomal DNA reactivates MAPK signaling independently of EGFR, driving acquired erlotinib resistance and revealing a targetable mechanism.
#STTT #OpenAccess: doi.org/10.1038/s413...
#OncogeneAmplification #CancerGenomics
@cancertherapyadv.bsky.socialFirst-line trastuzumab deruxtecan (T-DXd) prolongs PFS, but not overall survival, in metastatic, HER2-mutant #NSCLC
Julia Rotow, MD, from @danafarber.bsky.social presented research from the DESTINY-Lung 04 trial this week at #WCLC2026 @iaslc.bsky.social
Full article: https://bit.ly/4gY7oK6
@yalecancer.bsky.social#Osimertinib appears to β¬οΈ the elevated brain metastasis risk historically associated with two common subtypes of EGFR mutations, supporting osimertinib's role as a preferred first-line treatment for EGFR-mutant #NSCLC.
medicine.yale.edu/cancer/publi...
@oncoalert.bsky.social
@onc-rg.bsky.social
@4040rec.bsky.social